Recent Updates — AIMD

Ainos, Inc. entered into a Global Exclusive License Agreement with BioPhoenix Co., Ltd. on September 24, 2026, granting worldwide rights to research, develop, and commercialize its VELDONA® low-dose oral interferon alpha technology for Sjögren’s Disease and Thrombocytopenia. BioPhoenix will fund and execute clinical and regulatory activities, reducing Ainos' capital requirements. The agreement includes an upfront license fee of $600,000 payable upon completion of data package delivery and technology transfer. Additional potential fees include a one-time payment for the first sublicense and up to approximately $10 million in total license fees if all additional indications are licensed. Ainos retains 25% of BioPhoenix’s net sublicensing revenue for the Licensed Indications. The company operates in the biotechnology and artificial intelligence sectors, developing chemical sensing technologies and pharmaceutical platforms.

Ainos, Inc. reported financial results for the quarter ended June 30, 2026. The company generated $152 in revenue and incurred a net loss of $4,594,731, or $0.62 per share. Cash and cash equivalents increased to $1,422,912 from $417,353 at year-end 2025. The company advanced deployments for a previously announced $2.1 million commercial arrangement in semiconductor manufacturing and expanded pilot programs across industrial, healthcare, and robotics sectors. Ainos operates in the artificial intelligence and biotechnology industries, developing an electronic nose platform called AI Nose and immune therapeutics.